16.11.2014 Views

European Journal of Medical Research - Deutsche AIDS ...

European Journal of Medical Research - Deutsche AIDS ...

European Journal of Medical Research - Deutsche AIDS ...

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

June 27, 2007 EUROPEAN JOURNAL OF MEDICAL RESEARCH<br />

115<br />

E.3 (Poster)<br />

Mechanisms <strong>of</strong> HIV–1 resistance to a<br />

membrane-bound entry inhibitor<br />

Hermann F. 1 , Lohrengel S. 2 , Dittmar M. 2 , Dietrich U. 1 ,<br />

von Laer D. 1<br />

1 Georg-Speyer-Haus, Angewandte Virologie und Gentherapie,<br />

Frankfurt, Germany, 2 Universitätsklinikum Heidelberg,<br />

Hygiene-Institut, Heidelberg, Germany<br />

Objective: HIV entry into CD4 positive T cells is mediated<br />

by its trimeric envelope (env) surface protein. Env consists <strong>of</strong><br />

the receptor binding subunit gp120 and the transmembrane<br />

subunit gp41 which facilitates the fusion <strong>of</strong> viral and cellulare<br />

membrane. The process <strong>of</strong> virus binding and fusion is accompanied<br />

by extensive conformational rearrangements within<br />

the env protein. The conformational changes in gp41 lead to<br />

the formation <strong>of</strong> the 6-helix bundle, which is crucial for the<br />

fusion process. So called C-peptides (e.g. T-20), which are<br />

derived from gp41 are efficient inhibitors <strong>of</strong> viral fusion as<br />

they prevent 6-helix bundle formation. In our group a retroviral<br />

vector (M87o) has been developed encoding a membraneanchored<br />

C-peptide (maC46). maC46 is highly active even<br />

against T-20 resistant virus strains. It was the aim <strong>of</strong> this project<br />

to raise a maC46 resistant virus strain. The resistant virus<br />

was genetically as well as phenotypically analyzed.<br />

Methods: The CCR5-tropic virus strain BaL sel. MD (resistant<br />

to a membrane-bound version <strong>of</strong> T-20) was passaged on<br />

different retroviraly transduced PM-1 T cell lines for more<br />

than 150 days, which expressed maC46 at increasing levels.<br />

The env gene sequence <strong>of</strong> the passaged virus was determined.<br />

The mutant env was used to pseudotype lentiviral vectors.<br />

The particles were used for various single round infection assays<br />

to analyse the mechanism <strong>of</strong> resistance.<br />

Results: The maC46 resistance <strong>of</strong> the selected virus was only<br />

weak (app. 5-7 times compared to the parental strain). 5 mutations<br />

leading to aa changes could be identified within the env<br />

gene <strong>of</strong> the passaged virus. 3 alteration within gp120 (I187;<br />

N305, E353) and 2 mutations in gp41 (V556, A579) could be<br />

found. The mutations within gp41 were not sufficient to produce<br />

the resistant phenotype. The selected virus shows an increased<br />

fusion kinetic, although coreceptor affinity is reduced.<br />

Conclusion: It has been previously reported the fusion kinetic<br />

influences the sensitivity <strong>of</strong> HIV to C-peptide fusion inhibitors,<br />

but this is the first time that it could be shown that HIV actually<br />

employs this mechanism to gain resistance. We could show that<br />

the some resistance mutation have a global effect and lie far<br />

away from the region which is targeted by maC46 within gp41.<br />

E.4 (Vortrag)<br />

Selection <strong>of</strong> peptides inhibiting different steps in<br />

the HIV-1 replication cycle from phage displayed<br />

peptide libraries<br />

Dietrich U. 1 , Dietz J. 1 , Hüther A. 1 , Dervillez X. 2 ,<br />

Kräusslich H.-G. 3 , Königs C. 4 , Humbert M. 5<br />

1 Georg-Speyer-Haus, Frankfurt, Germany, 2 Hôpital Pitié<br />

Salpêtrière, Paris, France, 3 University Clinics, Virology,<br />

Heidelberg, Germany, 4 JW Goethe University, Pediatrics III,<br />

Frankfurt, Germany, 5 Dana Farber Cancer Institute, Boston,<br />

United States <strong>of</strong> America<br />

Objectives: The aim <strong>of</strong> this study was the selection <strong>of</strong> peptide<br />

ligands for different viral and cellular targets in order to interfere<br />

with HIV-1 replication at various steps <strong>of</strong> the replication<br />

cycle.<br />

Methods: Recombinant target proteins for the selection <strong>of</strong><br />

peptide ligands were expressed in E. coli or eukaryotic cells.<br />

Peptide ligands for various immobilized targets were selected<br />

from phage displayed peptide libraries (NEN Biolabs) that express<br />

peptides <strong>of</strong> 7 or 12 amino acids in length in a linear or<br />

cyclic form fused to the phage pIII protein. Specificity <strong>of</strong><br />

binding <strong>of</strong> the selected phages was confirmed by ELISA and<br />

the peptide sequences were deduced from the corresponding<br />

nucleotide sequences <strong>of</strong> the phage genomes. The selected<br />

peptides were tested for antiviral activity against HIV-1 in<br />

functional cell culture assays (single round infection assays,<br />

marker gene transduction assays).<br />

Results: We could select peptide ligands for various target<br />

structures including HIV-neutralizing antibodies, the viral envelope<br />

protein gp120, the highly structured psi-RNA containing<br />

the packaging signal for viral genome encapsidation as<br />

well as for the multimerizing domain <strong>of</strong> Gag. Some <strong>of</strong> the<br />

peptide ligands were optimized by mutagenesis or their functionality<br />

was improved by multimerization. Functional analyses<br />

<strong>of</strong> the selected peptides revealed interference with HIV-1<br />

replication at different steps <strong>of</strong> the viral replication cycle (entry,<br />

packaging, multimerization) depending on the target<br />

structures used for selection.<br />

Conclusion: The selected peptides represent good candidates<br />

for the derivation <strong>of</strong> peptidic or non-peptidic antiviral molecules.<br />

E.5 (Vortrag)<br />

Novel role for HIV-1 transframe protein p6* in<br />

viral replication<br />

Leiherer A. 1 , Ludwig C. 1 , Wagner R. 1<br />

1 Universität Regensburg, Institut für Medizinsche<br />

Mikrobiologie und Hygiene, Molekulare Mikrobiologie und<br />

Gentherapie, Regensburg, Germany<br />

Objective: The HIV-1 transframe protein p6* is encoded by<br />

the very 5´end <strong>of</strong> the pol gene and so its reading frame overlaps<br />

with p1 and p6 in the gag readingframe and the highly<br />

conserved ribosomal frameshift site. The p6* protein is located<br />

between nucleocapsid (NC) and protease (PR) in the Gagpol<br />

polyprotein precursor. Besides its aminotermius, also the<br />

carboxyterminal portion <strong>of</strong> p6* is highly conserved and has<br />

been reported to play a role in regulation <strong>of</strong> HIV-1 protease<br />

activation. Previously it has been suggested that the Nef protein,<br />

a key player <strong>of</strong> HIV-1 infectivity and progression to<br />

<strong>AIDS</strong>, binds to p6* to facilitate viral replication. This prompted<br />

us to analyze the role <strong>of</strong> p6* for HIV-1 replication.<br />

Methods: A panel <strong>of</strong> recombinant NL4-3-derived proviruses<br />

either containing or lacking nef was generated comprising<br />

clustered mutations throughout the p6* coding region without<br />

manipulating the gag open reading frame or affecting proper<br />

frameshifting or release <strong>of</strong> the viral protease. Besides, the role<br />

<strong>of</strong> a central p6* domain duplicated in the nef-negative virus<br />

HX10 was addressed by inserting this region into wild-type<br />

NL4-3. The effect <strong>of</strong> these mutations on viral infectivity and<br />

replication has been examined in cell culture.<br />

Results: Partially mutated p6* variants did not significantly<br />

influence viral infectivity or replication <strong>of</strong> the corresponding<br />

viruses. However, mutation <strong>of</strong> the entire p6* region decreased<br />

significantly viral infectivity irrespective <strong>of</strong> nef expression.<br />

Whereas this fully mutated p6* delayed the replication <strong>of</strong> nef-

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!